Posición sobre los pacientes portadores de hipertensión arterial en tratamiento con fármacos que actúan sobre el Sistema Renina Angiotensina Aldosterona y COVID-19
Palabras clave:
COVID-19; coronavirus; SARS-CoV-2; síndrome respiratorio agudo grave; hipertensión arterial; sistema renina angiotensina aldosterona
Citas
1) O’Mara GJ. Could ACE inhibitors, and particularly ARBs, Increase susceptibility to COVID-19 infection? Response to the emerging novel coronavirus outbreak. BMJ. 2020;368:m406. doi: 10.1136/bmj.m406.
2) Sriram K, Insel PA. Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence [preprint]. medRxiv. Posted Apr 20, 2020. doi: 10.1101/2020.03.25.20043927.
3) De Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. May 14, 2020. doi: 10.1016/S0140-6736(20)31030-8.
4) Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Med. 2005;11(8):875-9.
5) Imai Y, Kuba K, Rao S, Guo F, Guan V, Yang P, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112‐6. doi: 10.1038/nature03712.
6) Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21(1):305. doi: 10.1186/s13054-017-1882-z.
7) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19 [published online 2020 May 1, and updated on May 8]. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.
8) Chung SC, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom [published online 2020 May 8]. N Engl J Med. 2020;NEJMc2005396. doi: 10.1056/NEJMc2005396.
2) Sriram K, Insel PA. Dangers of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence [preprint]. medRxiv. Posted Apr 20, 2020. doi: 10.1101/2020.03.25.20043927.
3) De Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. May 14, 2020. doi: 10.1016/S0140-6736(20)31030-8.
4) Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Med. 2005;11(8):875-9.
5) Imai Y, Kuba K, Rao S, Guo F, Guan V, Yang P, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112‐6. doi: 10.1038/nature03712.
6) Zhang H, Baker A. Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care. 2017;21(1):305. doi: 10.1186/s13054-017-1882-z.
7) Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN, et al. Cardiovascular disease, drug therapy, and mortality in Covid-19 [published online 2020 May 1, and updated on May 8]. N Engl J Med. 2020; NEJMoa2007621. doi: 10.1056/NEJMoa2007621.
8) Chung SC, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom [published online 2020 May 8]. N Engl J Med. 2020;NEJMc2005396. doi: 10.1056/NEJMc2005396.
Publicado
2020-09-16
Cómo citar
1.
Blanco C, Bueno D, Lavenia G, Krämer C, Inserra F, Sivak L. Posición sobre los pacientes portadores de hipertensión arterial en tratamiento con fármacos que actúan sobre el Sistema Renina Angiotensina Aldosterona y COVID-19. Rev Nefrol Dial Traspl. [Internet]. 16 de septiembre de 2020 [citado 27 de diciembre de 2024];40(3):191-3. Disponible en: http://vps-1689312-x.dattaweb.com/index.php/rndt/article/view/531
Sección
Editorial
Derechos de autor 2020 Revista de Nefrología, Diálisis y Trasplante
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
